Post-earnings recap
Reported
Thu, Feb 23, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.42% following the earnings report, likely due to the lack of revenue data and overall market concerns. Investors may be cautious as management did not provide guidance for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.39 | N/A | +34.86% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding market conditions. They reiterated their commitment to long-term growth strategies.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current pressures.